Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop val... Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants. Mehr anzeigen
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver...
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs...
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on...
SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.28 | -11.3274336283 | 11.3 | 12.5799 | 9.54 | 194991 | 10.72300306 | CS |
| 4 | -6.01 | -37.492202121 | 16.03 | 16.03 | 9.54 | 119335 | 11.67628473 | CS |
| 12 | -4.04 | -28.733997155 | 14.06 | 19 | 9.54 | 72091 | 12.80833982 | CS |
| 26 | -1.36 | -11.9507908612 | 11.38 | 19 | 8.26 | 67155 | 12.55435096 | CS |
| 52 | -10.98 | -52.2857142857 | 21 | 30.4 | 8.26 | 74169 | 15.54985481 | CS |
| 156 | 3.02 | 43.1428571429 | 7 | 30.4 | 5.88 | 79450 | 15.879469 | CS |
| 260 | 3.02 | 43.1428571429 | 7 | 30.4 | 5.88 | 79450 | 15.879469 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
